全文获取类型
收费全文 | 2634篇 |
免费 | 274篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 81篇 |
妇产科学 | 65篇 |
基础医学 | 252篇 |
口腔科学 | 11篇 |
临床医学 | 248篇 |
内科学 | 395篇 |
皮肤病学 | 27篇 |
神经病学 | 100篇 |
特种医学 | 30篇 |
外国民族医学 | 5篇 |
外科学 | 125篇 |
综合类 | 334篇 |
预防医学 | 144篇 |
眼科学 | 22篇 |
药学 | 508篇 |
2篇 | |
中国医学 | 103篇 |
肿瘤学 | 498篇 |
出版年
2024年 | 2篇 |
2023年 | 42篇 |
2022年 | 68篇 |
2021年 | 90篇 |
2020年 | 88篇 |
2019年 | 95篇 |
2018年 | 141篇 |
2017年 | 116篇 |
2016年 | 105篇 |
2015年 | 112篇 |
2014年 | 194篇 |
2013年 | 191篇 |
2012年 | 154篇 |
2011年 | 209篇 |
2010年 | 168篇 |
2009年 | 132篇 |
2008年 | 129篇 |
2007年 | 137篇 |
2006年 | 79篇 |
2005年 | 102篇 |
2004年 | 80篇 |
2003年 | 63篇 |
2002年 | 58篇 |
2001年 | 55篇 |
2000年 | 47篇 |
1999年 | 37篇 |
1998年 | 18篇 |
1997年 | 16篇 |
1996年 | 13篇 |
1995年 | 23篇 |
1994年 | 20篇 |
1993年 | 21篇 |
1992年 | 17篇 |
1991年 | 17篇 |
1990年 | 22篇 |
1989年 | 16篇 |
1988年 | 10篇 |
1987年 | 9篇 |
1986年 | 8篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 7篇 |
1982年 | 9篇 |
1981年 | 4篇 |
1980年 | 5篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1974年 | 1篇 |
排序方式: 共有2953条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
《Saudi Pharmaceutical Journal》2022,30(6):849-855
The emergence of carbapenem-resistant organisms posed considerable threat to global health while only limited treatment options are available and led to efforts to discover a novel way to treat them. To evaluate in vitro synergistic activity of meropenem plus ertapenem, a total of 203 carbapenem-resistant strains, collected from 12 provinces and municipalities in China, were examined with a dual carbapenem combination therapy. The statistical software R was used for analysis. Two hundred and one (201) of carbapenem-resistant strains mainly produced four types of carbapenemase: KPC-2 (n = 142, 69.95%), OXA-232 (n = 7, 3.45%), NDM (n = 38, 18.72%; 36 NDM-1, 1 NDM-4, 1 NDM-5), and IMP (n = 15, 7.39%; 1 IMP-26, 10 IMP-30, 4 IMP-4). Fifty-one out of two hundred and three (51/203 or 25.12%) of the examined strains showed a synergistic effect for the meropenem plus ertapenem combination throughout the checkerboard method, while only three isolates showed potential clinically relevant synergy (3/203, 1.48%). An additive effect was observed in 55/203 (27.09%) of the examined strains. Ninety-seven of the examined isolates (47.78%) showed fractional inhibitory concentration (FIC) greater or equal to 2 (indicating antagonism). The synergistic activity of meropenem plus ertapenem combination suggests this combination can be a possible way to treat the infection caused by the carbapenem-resistant organisms, especially for IMP or NDM producer with a lesser minimum inhibitory concentration (MIC) and the infected individual who was not recommended to use colistin or tigecycline. 相似文献
3.
目的:探讨Zeste基因增强子(enhancer of zeste homolog 2,EZH2)对弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)RCHOP方案治疗的效果的预测价值。方法:纳入2017年1月至2018年5月南华大学附属第二医院80例接受RCHOP方案治疗的DLBCL患者,分析患者EZH2表达情况与治疗效果的关系,绘制EZH2预测治疗效果的ROC曲线,并对患者pCR与病理特征的关系进行讨论。结果:80例患者中EZH2高表达者49例,EZH2低表达者31例,DLBCL患者RCHOP治疗的pCR率为51.25%,其中EZH2高表达患者完全缓解(complete response,CR)、客观缓解率(objective response rate,ORR)均明显低于EZH2低表达患者(P<0.05);EZH2预测治疗效果的曲线下面积为0.874(P<0.05);pCR与性别、年龄、美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)得分、淋巴瘤国际预后指数(International Prognostic Index,IPI)得分、乳酸脱氢酶(lactate dehydrogenase,LDH)因素无相关关系(P>0.05);与Hans分型、EZH2表达水平存在一定的相关性(P<0.05)。结论:DLBCL患者EZH2低表达是RCHOP治疗后高pCR率的预测因子,在临床上有助于为DLBCL患者临床治疗提供更好的指导。 相似文献
4.
5.
《Research in social & administrative pharmacy》2022,18(9):3687-3693
IntroductionNew and flexible multidisciplinary workforce models are needed to address unnecessary medication regimen complexity in residential aged care facilities (RACFs). This study will investigate the feasibility of a nurse practitioner-pharmacist telehealth-based collaborative care model to simplify complex medication regimens.MethodsThis is a pragmatic, non-randomized pilot and feasibility study of up to 30 permanent residents from 4 RACFs in Western Australia. Simplification will be conducted in accordance with a validated 5-step implicit process. Nurse practitioners will identify residents potentially interested in and who may benefit from simplification, including any regulatory or safety imperatives that might preclude simplification. Medication regimens will be assessed by an off-site clinical pharmacist to identify opportunities for simplification in terms of drug–drug, drug–food, or drug–time interactions, and the availability of alternative formulations. The pharmacist will communicate simplification opportunities to nurse practitioners via video case conferencing. Nurse practitioners will then discuss simplification opportunities with the resident, caregiver and the health and care team, including any unintended consequences for the resident or RACF. The primary outcome measure will be feasibility (stakeholder acceptability, protocol adherence, recruitment and retention rates). Secondary outcomes include change in the number of medication administration times per day, medication and behavioral incidents, falls and fractures, hospitalization and mortality at 4 months.Ethics and disseminationEthical approval has been obtained from the Monash University Human Research Ethics Committee. Research findings will be disseminated through industry report, lay summaries, conference presentations and peer-reviewed publications. 相似文献
6.
Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome
《Best Practice & Research: Clinical Haematology》2019,32(3):239-252
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common types of cutaneous lymphoma, accounting for approximately 60% of cutaneous T-cell lymphomas. Diagnosis requires correlation of clinical, histologic, and molecular features. A multitude of factors have been linked to the aetiopathogenesis, however, none have been definitively proven. Erythrodermic MF (E-MF) and SS share overlapping clinical features, such as erythroderma, but are differentiated on the degree of malignant blood involvement. While related, they are considered to be two distinct entities originating from different memory T cell subsets. Differential expression of PD-1 and KIR3DL2 may represent a tool for distinguishing MF and SS, as well as a means of monitoring treatment response. Treatment of E-MF/SS is guided by disease burden, patients’ ages and comorbidities, and effect on quality of life. Current treatment options include biologic, targeted, immunologic, and investigational therapies that can provide long term response with minimal side effects. Currently, allogeneic stem cell transplantation is the only potential curative treatment. 相似文献
7.
8.
王春华 《中国继续医学教育》2020,(11):115-117
目的探讨急诊治疗重症心力衰竭的方案及疗效。方法选择本院80例2016年2月-2019年2月重症心力衰竭患者。随机分组,常规治疗组采取常规方法治疗,急诊治疗组则采取全面急诊治疗。比较两组重症心力衰竭疗效;重症心力衰竭症状改善的时间、心功能改善两级的时间;治疗前后患者舒张压、平均心率以及左心射血分数;不良反应。结果急诊治疗组重症心力衰竭疗效、重症心力衰竭症状改善的时间、心功能改善两级的时间、舒张压、平均心率以及左心射血分数相比较常规治疗组更好,P<0.05。两组未见严重不良反应,P>0.05。结论全面急诊治疗重症心力衰竭可获得较好预后,可有效改善患者的心功能,缓解症状,且安全性高,无明显不良反应。 相似文献
9.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
10.
目的 探讨儿童双相情感障碍经不同药物方案治疗后代谢指标的变化及治疗疗效。方法 回顾性分析2017年1月至2020年1月于该院就诊的220例儿童双相情感障碍患儿的临床资料。根据治疗方法分组,单纯采用非典型抗精神病药物治疗的112例患儿纳入对照组,采用非典型抗精神病药物联合心境稳定剂治疗的108例患儿纳入研究组。比较两组基线资料水平,治疗前后代谢指标空腹胰岛素(FIN)、糖化血红蛋白(HbAlc)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平变化,以及代谢综合征发生情况及临床疗效。结果 两组患儿年龄、性别、病程等基线资料比较差异均无统计学意义(P > 0.05)。研究组总有效率为92.6%,高于对照组(82.1%,P < 0.05)。治疗前,两组FIN、HbAlc水平比较差异无统计学意义(P > 0.05);治疗后,对照组FIN水平高于治疗前,且高于研究组(P < 0.05);但研究组治疗前后FIN水平比较差异无统计学意义(P > 0.05);两组治疗前后HbAlc水平比较差异无统计学意义(P > 0.05)。治疗前,两组TC、TG、HDL-C、LDL-C水平比较,差异无统计学意义(P > 0.05);治疗后,对照组TC、TG水平均高于治疗前,且高于研究组(P < 0.05);但研究组治疗前后TC、TG水平比较差异无统计学意义(P > 0.05);两组治疗前后HDL-C、LDL-C水平比较差异无统计学意义(P > 0.05)。研究组代谢综合征发生率(2.8%)低于对照组(9.8%)(P < 0.05)。结论 儿童双相情感障碍采用非经典抗精神病药物联合心境稳定剂治疗对代谢指标水平影响较小,且疗效显著。 相似文献